270 related articles for article (PubMed ID: 30054710)
1. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
Shibuya H; Hijioka S; Sakamoto Y; Ito T; Ueda K; Komoto I; Kobayashi N; Kudo A; Yasuda H; Miyake H; Arita J; Kiritani S; Ikeda M; Imaoka H; Ueno M; Kobayashi S; Furuta M; Nagashio Y; Murohisa G; Aoki T; Matsumoto S; Motoya M; Azemoto N; Itakura J; Horiguchi S; Yogi T; Kawagoe T; Miyaoka Y; Imamura F; Senju M; Arioka H; Hara K; Imamura M; Okusaka T
Cancer Chemother Pharmacol; 2018 Oct; 82(4):661-668. PubMed ID: 30054710
[TBL] [Abstract][Full Text] [Related]
2. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan.
Aoki T; Kokudo N; Komoto I; Takaori K; Kimura W; Sano K; Takamoto T; Hashimoto T; Okusaka T; Morizane C; Ito T; Imamura M
J Gastroenterol; 2015 Jul; 50(7):769-75. PubMed ID: 25348496
[TBL] [Abstract][Full Text] [Related]
3. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
4. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
5. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
[TBL] [Abstract][Full Text] [Related]
6. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
8. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
Krug S; Boch M; Daniel H; Nimphius W; Müller D; Michl P; Rinke A; Gress TM
PLoS One; 2015; 10(12):e0143822. PubMed ID: 26630134
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
[TBL] [Abstract][Full Text] [Related]
10. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.
Komoto I; Kokudo N; Aoki T; Morizane C; Ito T; Hashimoto T; Kimura W; Inoue N; Hasegawa K; Kondo S; Ueno H; Igarashi H; Oono T; Makuuchi M; Takamoto T; Hirai I; Takeshita A; Imamura M
Jpn J Clin Oncol; 2022 Jul; 52(7):716-724. PubMed ID: 35411926
[TBL] [Abstract][Full Text] [Related]
12. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
Mueller D; Krug S; Majumder M; Rinke A; Gress TM
BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
[TBL] [Abstract][Full Text] [Related]
13. Streptozocin-based chemotherapy is not history in neuroendocrine tumours.
Weatherstone K; Meyer T
Target Oncol; 2012 Sep; 7(3):161-8. PubMed ID: 22899468
[TBL] [Abstract][Full Text] [Related]
14. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
15. Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors.
Schrader J; Henes FO; Blaeker M; Zimmermann-Fraedrich K; Pace A; Perez D; Izbicki JR; Lohse AW; Benten D
Endocrine; 2019 Aug; 65(2):460-467. PubMed ID: 31037707
[TBL] [Abstract][Full Text] [Related]
16. A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.
Naidoo J; O'Toole D; Kennedy MJ; Reynolds JV; O'Connor M; O'Byrne K
Ir J Med Sci; 2012 Jun; 181(2):211-4. PubMed ID: 22048868
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
Turner NC; Strauss SJ; Sarker D; Gillmore R; Kirkwood A; Hackshaw A; Papadopoulou A; Bell J; Kayani I; Toumpanakis C; Grillo F; Mayer A; Hochhauser D; Begent RH; Caplin ME; Meyer T
Br J Cancer; 2010 Mar; 102(7):1106-12. PubMed ID: 20234360
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of streptozocin-based chemotherapy for gastroenteropancreatic neuroendocrine tumors in Japanese clinical practice.
Murakami M; Fujimori N; Takamatsu Y; Ito T; Matsumoto K; Kakehashi S; Ohno A; Teramatsu K; Ueda K; Ishigami K; Ogawa Y
Jpn J Clin Oncol; 2024 Jun; 54(6):647-657. PubMed ID: 38422348
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
